QUAZAR AML-001 Multivariate Analysis: Predictors of Survival Outcomes With Oral Azacitidine (CC-486) Among Patients With AML in Remission After Intensive Chemotherapy
June 4-8, 2021; Online at https://conferences.asco.org/am
Cytogenetic risk and MRD status identified as independent predictors of overall survival and relapse-free survival with oral azacytidine in this multivariate analysis.
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.